Does herpes cause cancer? Some herpesviruses do, but not the common ones people worry about. Epstein-Barr virus (EBV) and Kaposi sarcoma-associated herpesvirus (KSHV) are classified as human carcinogens and drive several cancers. Herpes simplex virus (HSV-1 and HSV-2), which causes cold sores and genital herpes, is not known to cause cancer in humans.
That distinction matters because "herpes" covers a family of eight human viruses with wildly different biology. Two of them are directly carcinogenic. Two more — cytomegalovirus and human herpesvirus 6 — have been detected in tumor tissue but lack established causal roles. The remaining four have no credible cancer link. The answer depends entirely on which virus you mean, and that specificity is what most short explainers skip.
Two distinct routes to malignancy
Herpesviruses cause cancer through two fundamentally different strategies, and understanding why they work requires looking at how each virus manages its own replication.
EBV, a gammaherpesvirus carried by roughly 90 to 95 percent of adults worldwide, establishes latency in B lymphocytes. During latency it expresses only a handful of proteins, which lets it hide from immune detection. But two of those latent proteins — LMP1 and LMP2A — mimic constitutively active cellular receptors. LMP1 behaves like a permanently switched-on tumor necrosis factor receptor, driving the NF-κB survival pathway without any external signal. LMP2A mimics the B-cell receptor and delivers survival signals that would normally require antigen stimulation. The infected B cell stays alive and keeps dividing when it should have died, and that survival pressure is the first step toward lymphoma.
KSHV works differently. It establishes latency in endothelial cells and B cells and expresses a suite of proteins that disable the cell's own tumor suppressors. The latent protein LANA binds and inactivates p53 and retinoblastoma protein, the two major brakes on cell division. KSHV also carries viral homologs of human genes — a viral cyclin, a viral interleukin-6, a viral BCL-2 — that were captured from the host genome and rewired for the virus's benefit. These homologs push proliferation and block apoptosis simultaneously.
HSV-1 and HSV-2 lack these tools. They replicate lytically, destroy the cells they infect, and retreat into sensory neurons where they express almost nothing. A virus that kills its host cell quickly has no evolutionary incentive to keep it alive and dividing. That is the mechanistic reason HSV is not carcinogenic: it has no latency program built for cell survival.
The plain version: EBV and KSHV carry molecular machinery designed to keep infected cells alive and multiplying. HSV destroys cells rather than preserving them.
The numbers behind the link
The quantified picture separates these viruses sharply. EBV is associated with approximately 200,000 new cancer cases annually worldwide, according to estimates synthesized in the scientific literature. That places it among the most consequential infectious carcinogens, behind human papillomavirus but ahead of most others.
The specific cancers and their EBV attribution rates vary widely. Burkitt lymphoma is EBV-positive in roughly 95 percent of cases in equatorial Africa but only about 15 to 20 percent elsewhere, a geographic split that suggests cofactors like malaria matter enormously. Nasopharyngeal carcinoma is nearly 100 percent EBV-associated in high-incidence regions of southern China and Southeast Asia. Hodgkin lymphoma shows EBV positivity in about 40 percent of cases in developed countries. Post-transplant lymphoproliferative disorder is EBV-driven in the large majority of cases, reflecting immunosuppression that lets latently infected B cells expand unchecked.
KSHV is far rarer but more tightly linked. Kaposi sarcoma is essentially defined by KSHV presence, and the virus is found in nearly 100 percent of KS lesions. Primary effusion lymphoma and multicentric Castleman disease are also KSHV-driven. The global burden is concentrated in sub-Saharan Africa and among people with HIV.
For context, HSV-1 and HSV-2 infect billions of people worldwide — HSV-1 alone affects an estimated 3.7 billion people under age 50, per WHO figures. If HSV caused cancer at any meaningful rate, the signal would be overwhelming and obvious. It is not there.
When the same virus behaves differently
The most instructive edge cases show that infection is necessary but rarely sufficient. EBV is nearly universal, yet Burkitt lymphoma is rare. Something else must be happening.
In endemic Burkitt lymphoma, chronic malaria infection drives repeated B-cell activation and suppresses T-cell surveillance, creating a large pool of EBV-infected cells that can accumulate the chromosomal translocation — typically involving the MYC oncogene — that completes the transformation. Neither malaria nor EBV alone produces the cancer. The combination does.
Immunosuppression is the other great revealer. Transplant recipients on calcineurin inhibitors lose T-cell control of EBV-infected B cells and can develop post-transplant lymphoproliferative disorder within months. People with advanced HIV lose the same surveillance and face sharply elevated risks of both EBV-driven lymphomas and KSHV-driven Kaposi sarcoma. Restore the immune system — reduce immunosuppression, start antiretroviral therapy — and these tumors can regress without any direct anticancer drug. That reversibility is strong evidence that immune control, not viral presence alone, determines outcome.
A counterintuitive professional caveat: detecting EBV DNA in a tumor does not prove causation. EBV DNA appears in saliva and blood of healthy people routinely, and sensitive assays find viral sequences in tissues incidentally. Pathologists rely on consistency of association, presence in every tumor cell, and mechanistic plausibility — not mere detection.
What the evidence does not show
Several persistent misconceptions deserve direct correction.
HSV-1 and HSV-2 are not established carcinogens. The confusion often arises from antibody studies that found weak associations between HSV-2 seropositivity and cervical cancer. Those associations disappeared once HPV — the actual cause of nearly all cervical cancer — was controlled for. HSV-2 is a cofactor for HIV transmission, not a carcinogen.
Cytomegalovirus is frequently detected in glioblastoma tissue, and this has fueled claims that CMV drives brain tumors. The evidence remains correlational. CMV is a ubiquitous virus that reactivates in sick patients, so detection in tumor tissue may be a consequence of illness rather than a cause. No major health body classifies CMV as a human carcinogen.
A positive EBV antibody test does not mean cancer risk. Nearly everyone carries EBV. Routine EBV testing in healthy people has no cancer-screening value.
The bulleted red flags worth knowing:
New persistent lymph node swelling lasting more than four weeks, especially with fever or night sweats, warrants medical evaluation. Unexplained purple or brown skin lesions in anyone with HIV or transplant history should prompt KSHV evaluation. A positive EBV test in an otherwise healthy adult is not a cancer signal and needs no follow-up. Nasopharyngeal symptoms — persistent nasal obstruction, bloody discharge, hearing change — in people from high-incidence regions merit prompt ENT assessment. Persistent lymphadenopathy in a transplant recipient should trigger consideration of post-transplant lymphoproliferative disorder.
Comparing the human herpesviruses
| Virus | Primary cancers linked | Carcinogen classification | Population prevalence |
|---|---|---|---|
| EBV (HHV-4) | Burkitt lymphoma, nasopharyngeal carcinoma, Hodgkin lymphoma, post-transplant lymphoproliferative disorder, gastric cancer subset | Group 1 (IARC) | 90–95% of adults |
| KSHV (HHV-8) | Kaposi sarcoma, primary effusion lymphoma, multicentric Castleman disease | Group 1 (IARC) | Under 5% in most regions; higher in sub-Saharan Africa |
| HSV-1 | None established | Not classified | Roughly two-thirds of people under 50 (WHO) |
| HSV-2 | None established | Not classified | Estimated 500 million+ worldwide |
| CMV (HHV-5) | None established; detected in some tumors | Not classified | 50–80% of adults |
| HHV-6 | None established | Not classified | Nearly universal by age 2 |
IARC Group 1 means "carcinogenic to humans" based on sufficient evidence. The absence of a classification for HSV, CMV, and HHV-6 reflects lack of sufficient evidence, not proven safety — but decades of surveillance have produced no signal.
How cancer develops after infection
The time course differs by tumor type, and it explains why prevention windows exist.
| Stage | What happens | Typical timing |
|---|---|---|
| Primary infection | EBV or KSHV infects B cells or endothelial cells; usually asymptomatic | Childhood or early adulthood |
| Latency establishment | Virus persists in a small reservoir of cells with minimal gene expression | Weeks after infection |
| Immune control | T cells keep latently infected cells in check | Indefinite in healthy people |
| Immune disruption | HIV, transplant drugs, or malaria erode surveillance | Months to years later |
| Expanded reservoir | Infected cells proliferate; genetic errors accumulate | Years |
| Overt malignancy | Additional mutations complete transformation | Often 5–20 years after infection |
The long latency from infection to cancer is why the diseases appear in specific risk groups rather than in the general population. It is also why immune restoration is itself a preventive strategy.
Practical steps that reduce risk
For most people carrying EBV, which is most adults, no cancer-specific action is warranted. The practical measures target the modifiable cofactors.
People with HIV should maintain antiretroviral therapy. Viral suppression preserves immune surveillance and dramatically lowers Kaposi sarcoma and lymphoma risk. Transplant recipients should discuss individualized immunosuppression targets with their transplant team; lower doses reduce post-transplant lymphoproliferative disorder risk where clinically safe. People in or from malaria-endemic regions benefit from malaria prevention, which reduces the cofactor burden behind endemic Burkitt lymphoma. Anyone with unexplained persistent lymphadenopathy, night sweats, or weight loss lasting more than two to four weeks should seek medical evaluation rather than assume a benign cause. No vaccine is approved for EBV or KSHV, so prevention rests on immune preservation and cofactor control. HPV vaccination prevents cervical cancer but has no bearing on herpesvirus cancers.
Reconciling thresholds: the four-week node-persistence threshold is a general clinical trigger, not a cancer-specific cutoff. The relevant risk multiplier is immune status — a transplant recipient with two weeks of adenopathy warrants earlier attention than a healthy adult with four.
Limits of what the evidence can claim
The causal case for EBV and KSHV is strong but not complete. For EBV, the near-universal prevalence makes it statistically impossible to run a clean cohort comparison between infected and uninfected people. Causal claims rest on mechanistic evidence, consistency across tumor types, and the reversibility seen with immune restoration — a triangulation rather than a controlled trial.
For KSHV the picture is cleaner because prevalence is low, but the cancers are rare enough that precise global burden figures are uncertain. Estimates carry wide confidence intervals.
What remains genuinely unresolved: whether low-level EBV or KSHV reactivation contributes to cancers not currently attributed to them, and whether antiviral drugs could prevent KSHV-driven disease in high-risk groups. Trials of antiherpes drugs against EBV and KSHV cancers have largely disappointed, suggesting the viruses act early and then become dispensable — the so-called hit-and-run problem.
The honest bottom line is specific: the herpesviruses that cause cancer do so through defined molecular mechanisms, in defined risk groups, with defined cofactors. The common herpes viruses people fear do not. Conflating the family produces unnecessary anxiety about HSV and misses the real prevention opportunities in EBV and KSHV.